<DOC>
	<DOCNO>NCT02724254</DOCNO>
	<brief_summary>This double-blind placebo control , randomize , phase 2 study ass safety , tolerability , pharmacokinetics efficacy twice daily topical application AP611074 5 % Gel 16 week condyloma patient</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Efficacy Twice Daily Topical Applications AP611074 5 % Gel 16 Weeks Condyloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>1 . Male female patient age 18 55 year . 2 . External condylomas , 230 lesion 3 . Lesions must internal . Lesions originate internally , visible externally consider internal allow study . 4 . Total wart area ( diameter x diameter ) less 10mm2 800 mm2 5 . Lesions treat appear 1 6 month screen , patient receive previous condyloma treatment last 2 month enrollment . 6 . For female patient : either postmenopausal , take adequate contraceptive method surgically sterile . 1 . Patients ' total wart area decrease â‰¥50 % Screening Visit Randomization Visit ( Week 0 ) . 2 . Patients receive genital wart treatment previous condylomas ( prior treatment current condylomas refer inclusion criterion ) last 12 month enrollment 3 . Patients history presence cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurologic , psychiatric , systemic infectious disease , transplant immunosuppressed patient clinical condition , Investigator 's judgment , prevent patient participate study . 4 . Patients clinically significant abnormality follow review screen laboratory test , vital sign , full physical examination ECG . Liver enzymes : aspartate aminotransferase ( ASAT ) , alanine aminotransferase ( ALAT ) alkaline phosphatase ( ALP ) must within normal range . 5 . Patients history presence drug alcohol abuse . 6 . Patients positive HBs HBc antigen anti HCV antibody , positive result HIV 1 2 test . 7 . Patients use dermatological drug therapy treatment area last month prior first application study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Genital wart</keyword>
	<keyword>HPV type</keyword>
	<keyword>Sexually Transmitted Disease</keyword>
	<keyword>Papillomavirus Infections</keyword>
	<keyword>Viral Disease</keyword>
	<keyword>Anogenital wart</keyword>
	<keyword>AGW</keyword>
	<keyword>HPV6</keyword>
	<keyword>HPV11</keyword>
	<keyword>Human papillomavirus infection</keyword>
	<keyword>HPV</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>